Company Announcements

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Feb. 23, 2026-- Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company’s management team will participate in the following upcoming investor conferences:

• TD Cowen 46^th Annual Healthcare Conference, March 2-5, 2026
  • Format: Fireside chat and one-on-one meetings
  • Presentation Date & Time: March 3, 2026, 1:50 pm EST
  • Location: Boston, MA

• Jefferies 2026 Biotech on the Beach Summit, March 10-11, 2026
  • Format: One-on-one investor meetings
  • Location: Miami, FL

Available presentations will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the presentation.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates in depression, schizophrenia, and other mental health conditions. For more information, visit www.altoneuroscience.com or follow Alto on X.

Availability of Information on Alto’s Website

Alto routinely uses its investor relations website to post presentations to investors and other important information, including information that may be material. Accordingly, Alto encourages investors and others interested in Alto to review the information it makes public on its investor relations website.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260223767838/en/

Investor & Media Contact:
Nick Smith
investors@altoneuroscience.com

Source: Alto Neuroscience, Inc.